Streetbeat News

Stock Prices

MSI

Motorola Solutions (NYSE:MSI) has outperformed the market over the past 15 years, producing an average annual return of 14.35%. A $1000 investment in MSI 15 years ago would be worth $7,460.84 today.

Portfolio Pulse from Benzinga Insights

May 25, 2023 | 9:32 pm

MRK

Merck & Co (NYSE:MRK) has outperformed the market over the past 5 years by 6.03% on an annualized basis, producing an average annual return of 15.06%. A $100 investment in MRK 5 years ago would be worth $201.67 today.

Portfolio Pulse from Benzinga Insights

May 25, 2023 | 9:32 pm

CGC

CNVCF

FFNTF

Cannabis stocks experienced mixed results on May 25, 2023, with 4Front Ventures (FFNTF) gaining 6.25% while several others, including Canopy Gwth (CGC) and BioHarvest Sciences (CNVCF), saw significant losses.

Portfolio Pulse from Benzinga Insights

May 25, 2023 | 9:30 pm

BOH

HMST

KNF/V

Knife River Corporation (KNF/V) is set to join the S&P MidCap 400, replacing Bank of Hawaii (BOH), which will join the S&P SmallCap 600, replacing HomeStreet (HMST).

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 9:27 pm

IWD

IWF

Value stocks have fallen to a seven-month low in relation to growth stocks, with AI-related rallies propelling technology equities. The ratio between iShares Russell 1000 Value ETF (IWD) and iShares Russell 1000 Growth ETF (IWF) has reached levels not seen since January 2022, indicating underperformance of value-oriented companies.

Portfolio Pulse from Piero Cingari

May 25, 2023 | 9:18 pm

REGN

Regeneron reports positive early clinical trial results for the combination of LAG-3 inhibitor Fianlimab and PD-1 inhibitor Libtayo, showing clinically meaningful and durable results across multiple clinical settings. The data will be presented at the 2023 ASCO Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 9:15 pm

VSTM

Verastem has released updated data from Part A of its RAMP 201 trial, which focuses on the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL).

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 9:13 pm

SWTX

SpringWorks Therapeutics announced additional data from its Phase 3 DeFi trial of Nirogacestat in adults with desmoid tumors at the 2023 ASCO Meeting. The treatment demonstrated rapid, sustained, and consistent reductions in pain compared to placebo, as well as substantial reductions in MRI-assessed tumor volume and T2 hyperintensity.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 9:11 pm

INCY

Incyte announced that multiple abstracts featuring data from its oncology portfolio will be presented at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 9:08 pm

GNPX

Genprex published clinical data from the Phase 1 portion of the Acclaim-1 clinical trial evaluating REQORSA immunogene therapy in non-small cell lung cancer at the 2023 ASCO Annual Meeting. The combination of REQORSA and Tagrisso was well tolerated at all three dose levels, with encouraging evidence of efficacy observed.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 9:08 pm